Starpharma Holdings Limited (SPHRY)
USD 0.59
(0.0%)
USD 0.59
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -23.74 Million AUD | 3.76% |
| 2023 | -24.67 Million AUD | -3.26% |
| 2022 | -23.89 Million AUD | 16.65% |
| 2021 | -28.66 Million AUD | -33.79% |
| 2020 | -21.42 Million AUD | -5.08% |
| 2019 | -20.39 Million AUD | -31.69% |
| 2018 | -15.48 Million AUD | 18.94% |
| 2017 | -19.1 Million AUD | 24.53% |
| 2016 | -25.31 Million AUD | -33.61% |
| 2015 | -18.94 Million AUD | -29.51% |
| 2014 | -14.62 Million AUD | -180.23% |
| 2013 | -5.22 Million AUD | 61.76% |
| 2012 | -13.65 Million AUD | -53.13% |
| 2011 | -8.91 Million AUD | -40.09% |
| 2010 | -6.36 Million AUD | -47.94% |
| 2009 | -4.3 Million AUD | 47.03% |
| 2008 | -8.11 Million AUD | -2.33% |
| 2007 | -7.93 Million AUD | -5.8% |
| 2006 | -7.49 Million AUD | 1.03% |
| 2005 | -7.57 Million AUD | -38.13% |
| 2004 | -5.48 Million AUD | 27.14% |
| 2003 | -7.52 Million AUD | 15.1% |
| 2002 | -8.86 Million AUD | -58.82% |
| 2001 | -5.58 Million AUD | -57.56% |
| 2000 | -3.54 Million AUD | -51.56% |
| 1999 | -2.33 Million AUD | 8.0% |
| 1998 | -2.54 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -4.95 Million AUD | -858.03% |
| 2024 Q3 | -7.17 Million AUD | -44.93% |
| 2024 Q4 | -7.17 Million AUD | 0.0% |
| 2024 FY | -15.15 Million AUD | 38.56% |
| 2024 Q1 | -517 Thousand AUD | 95.49% |
| 2023 FY | -24.67 Million AUD | -3.26% |
| 2023 Q1 | -4.13 Million AUD | 64.18% |
| 2023 Q2 | -13.2 Million AUD | -219.15% |
| 2023 Q4 | -11.46 Million AUD | -210.2% |
| 2023 Q3 | -3.69 Million AUD | 72.02% |
| 2022 Q3 | -3.85 Million AUD | 68.79% |
| 2022 Q1 | -4.22 Million AUD | 69.85% |
| 2022 FY | -23.89 Million AUD | 16.65% |
| 2022 Q2 | -12.34 Million AUD | -192.15% |
| 2022 Q4 | -11.55 Million AUD | -199.88% |
| 2021 Q3 | -4.65 Million AUD | 68.27% |
| 2021 FY | -28.66 Million AUD | -33.79% |
| 2021 Q2 | -14.65 Million AUD | -181.05% |
| 2021 Q1 | -5.21 Million AUD | 57.57% |
| 2021 Q4 | -14.01 Million AUD | -201.27% |
| 2020 Q2 | -9.13 Million AUD | -211.72% |
| 2020 Q4 | -12.29 Million AUD | -178.87% |
| 2020 Q1 | -2.93 Million AUD | 71.07% |
| 2020 Q3 | -4.4 Million AUD | 51.77% |
| 2020 FY | -21.42 Million AUD | -5.08% |
| 2019 FY | -20.39 Million AUD | -31.69% |
| 2019 Q2 | -3.63 Million AUD | 0.0% |
| 2019 Q4 | -10.13 Million AUD | -190.01% |
| 2019 Q1 | -3.63 Million AUD | -79.14% |
| 2019 Q3 | -3.49 Million AUD | 3.83% |
| 2018 FY | -15.48 Million AUD | 18.94% |
| 2018 Q1 | -3.11 Million AUD | 9.49% |
| 2018 Q4 | -2.02 Million AUD | 0.0% |
| 2018 Q3 | -2.02 Million AUD | 34.89% |
| 2018 Q2 | -3.11 Million AUD | 0.0% |
| 2017 FY | -19.1 Million AUD | 24.53% |
| 2017 Q4 | -3.44 Million AUD | 0.0% |
| 2017 Q3 | -3.44 Million AUD | 17.43% |
| 2017 Q1 | -4.16 Million AUD | 15.59% |
| 2017 Q2 | -4.16 Million AUD | 0.0% |
| 2016 Q1 | -5.01 Million AUD | 3.63% |
| 2016 Q3 | -6.32 Million AUD | -26.01% |
| 2016 Q4 | -4.93 Million AUD | 21.88% |
| 2016 Q2 | -5.01 Million AUD | 0.0% |
| 2016 FY | -25.31 Million AUD | -33.61% |
| 2015 Q4 | -5.2 Million AUD | 0.0% |
| 2015 FY | -18.94 Million AUD | -29.51% |
| 2015 Q1 | -4.26 Million AUD | 5.77% |
| 2015 Q2 | -4.26 Million AUD | 0.0% |
| 2015 Q3 | -5.2 Million AUD | -21.97% |
| 2014 FY | -14.62 Million AUD | -180.23% |
| 2014 Q4 | -4.52 Million AUD | 0.0% |
| 2014 Q3 | -4.52 Million AUD | -62.62% |
| 2014 Q2 | -2.78 Million AUD | 0.0% |
| 2014 Q1 | -2.78 Million AUD | -64.16% |
| 2013 Q3 | -1.69 Million AUD | -85.71% |
| 2013 Q4 | -1.69 Million AUD | 0.0% |
| 2013 Q1 | -913.5 Thousand AUD | 0.0% |
| 2013 FY | -5.22 Million AUD | 61.76% |
| 2013 Q2 | -913.5 Thousand AUD | 0.0% |
| 2012 FY | -13.65 Million AUD | -53.13% |
| 2011 FY | -8.91 Million AUD | -40.09% |
| 2010 FY | -6.36 Million AUD | -47.94% |
| 2009 FY | -4.3 Million AUD | 47.03% |
| 2008 FY | -8.11 Million AUD | -2.33% |
| 2007 FY | -7.93 Million AUD | -5.8% |
| 2006 FY | -7.49 Million AUD | 1.03% |
| 2005 FY | -7.57 Million AUD | -38.13% |
| 2004 FY | -5.48 Million AUD | 27.14% |
| 2003 FY | -7.52 Million AUD | 15.1% |
| 2002 FY | -8.86 Million AUD | -58.82% |
| 2001 FY | -5.58 Million AUD | -57.56% |
| 2000 FY | -3.54 Million AUD | -51.56% |
| 1999 FY | -2.33 Million AUD | 8.0% |
| 1998 FY | -2.54 Million AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Biomind Labs Inc. | -1 Million USD | -2251.915% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 56.806% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -257.174% |
| Skye Bioscience, Inc. | -13.67 Million USD | -73.679% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -1173.621% |
| Mesoblast Limited | -84.14 Million USD | 71.782% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -79176.843% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -370.712% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -49.624% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -1128.649% |
| GB Sciences, Inc. | -1.42 Million USD | -1571.584% |
| MultiCell Technologies, Inc. | -722.81 USD | -3284995.668% |
| Alpha Cognition Inc. | -9.7 Million USD | -144.653% |
| HST Global, Inc. | -140.9 Thousand USD | -16751.54% |
| CSL Limited | 3.7 Billion USD | 100.641% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Agentix Corp. | -1.37 Million USD | -1630.993% |
| Halberd Corporation | -75.05 Thousand USD | -31538.907% |
| Enzolytics Inc. | -2.14 Million USD | -1005.035% |
| Resverlogix Corp. | -12.74 Million USD | -86.25% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -649.462% |
| argenx SE | -425.04 Million USD | 94.414% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -2174.425% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 770.763% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -597.361% |
| Bioxytran, Inc. | -3.82 Million USD | -521.573% |
| Zenith Capital Corp. | -8.94 Million USD | -165.515% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -867.085% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -13744.711% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -1084.433% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Genscript Biotech Corporation | -415.79 Million USD | 94.289% |
| Kadimastem Ltd | -3.04 Million USD | -681.021% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -2312.98% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -718.44% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -1790.525% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 343.727% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -421.327% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -533.805% |
| EV Biologics, Inc. | -483.06 Thousand USD | -4815.518% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -12983.726% |
| Q BioMed Inc. | -3.44 Million USD | -589.137% |
| LadRx Corporation | -3.82 Million USD | -521.007% |
| Cell Source, Inc. | -4.32 Million USD | -448.973% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -5615.09% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -3356.583% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 57.222% |
| Itoco Inc. | -919.14 Thousand USD | -2483.393% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -460.233% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -2010.843% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -713.34% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -2021.984% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -1403.462% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | 6.69 Million USD | 454.78% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -136201.016% |
| NovAccess Global Inc. | -2.46 Million USD | -862.599% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -94238.498% |
| BioStem Technologies, Inc. | -7.77 Million USD | -205.246% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -10689.357% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -1678.078% |
| Qrons Inc. | -643.67 Thousand USD | -3588.962% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -4104.716% |
| SYBLEU INC | -149.18 Thousand USD | -15817.013% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -964.856% |
| Rebus Holdings, Inc. | -664 Thousand USD | -3476.054% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -3356.583% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -1207.314% |
| Affymax, Inc. | -15.04 Million USD | -57.816% |
| Mobile Lads Corp. | -554.55 Thousand USD | -4181.85% |
| International Stem Cell Corporation | -663 Thousand USD | -3481.448% |
| CytoDyn Inc. | -18.05 Million USD | -31.493% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -45008.283% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -116640.413% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 34.525% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -1367.553% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -3126.946% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -663.259% |
| Neutra Corp. | -229.48 Thousand USD | -10247.036% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -35.384% |
| PureTech Health plc | -146.19 Million USD | 83.758% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -10.487% |
| IXICO plc | -1.43 Million USD | -1552.401% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -150.184% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 80.506% |
| CSL Limited | 3.81 Billion USD | 100.623% |
| Cellectis S.A. | -108.85 Million USD | 78.187% |